Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 40, 2012, Pages 16101-16106

  Axup, Jun Y ^a   Bajjuri, Krishna M ^a   Ritland, Melissa ^a   Hutchins, Benjamin M ^a   Kim, Chan Hyuk ^a   Kazane, Stephanie A ^a   Halder, Rajkumar ^a   Forsyth, Jane S ^a   Santidrian, Antonio F ^a   Stafin, Karin ^a   Lu, Yingchun ^b   Tran, Hon ^b   Seller, Aaron J ^b   Biroc, Sandra L ^b   Szydlik, Aga ^b   Pinkstaff, Jason K ^b   Tian, Feng ^b   Sinha, Subhash C ^a   Felding Habermann, Brunhilde ^a   Smider, Vaughn V ^a   Schultz, Peter G ^a   more..

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b AMBRX INC   (United States)

Author keywords

Breast cancer; Protein conjugation

Indexed keywords

AMINO ACID; ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CHEMOREACTIVITY; CONJUGATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SYNTHESIS; ESCHERICHIA COLI; IN VITRO STUDY; MAMMAL CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOICHIOMETRY; TUMOR XENOGRAFT;

AMINO ACIDS; AMINOBENZOATES; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG DISCOVERY; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; MICE; MICE, SCID; OLIGOPEPTIDES; PROTEIN ENGINEERING; RECEPTOR, ERBB-2;

ESCHERICHIA COLI; MAMMALIA; RODENTIA;

EID: 84867040452     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1211023109     Document Type: Article

References (43)

1. Wu AM, Senter PD (2005) Arming antibodies: Prospects and challenges for immunoconjugates. Nat Biotechnol 23:1137-1146. (Pubitemid 41486395)
2. Polakis P (2005) Arming antibodies for cancer therapy. Curr Opin Pharmacol 5:382-387.
3. Lambert JM (2005) Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol 5:543-549.
4. Vater CA, Goldmacher VS (2010) Antibody-cytotoxic compound conjugates for oncology. Macromolecular Anticancer Therapeutics Part 4:331-369.
5. Kovtun YV, Goldmacher VS (2007) Cell killing by antibody-drug conjugates. Cancer Lett 255:232-240. (Pubitemid 47268641)
6. Okeley NM, et al. (2010) Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 16:888-897.
7. Hamann PR, et al. (2002) Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 13:47-58. (Pubitemid 34119634)
8. Beck A, et al. (2010) The next generation of antibody-drug conjugates comes of age. Discov Med 10:329-339.
9. Francisco JA, et al. (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102:1458-1465. (Pubitemid 36988057)
10. Doronina SO, et al. (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity. Bioconjug Chem 17:114-124. (Pubitemid 43157592)
11. Lewis Phillips GD, et al. (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68:9280-9290.
12. Tolcher AW, et al. (2003) Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: A phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 21:211-222. (Pubitemid 46606149)
13. Goff LW, et al. (2009) A phase II study of IMGN242 (huC242-DM4) in patients with CanAg-positive gastric or gastroesophageal (GE) junction cancer. J Clin Oncol 27:e15625.
14. DiJoseph JF, et al. (2004) Antibody-targeted chemotherapy with CMC-544: A CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 103:1807- 1814.
15. Tse KF, et al. (2006) CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res 12:1373-1382. (Pubitemid 43342531)
16. Hamblett KJ, et al. (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10:7063-7070. (Pubitemid 39383058)
17. Wang L, Amphlett G, Blättler WA, Lambert JM, Zhang W (2005) Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci 14:2436-2446. (Pubitemid 41252812)
18. Junutula JR, et al. (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26:925-932.
19. Junutula JR, et al. (2010) Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res 16:4769-4778.
20. Shen B-Q, et al. (2012) Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 30:184-189.
21. Wang L, Brock A, Herberich B, Schultz PG (2001) Expanding the genetic code of Escherichia coli. Science 292:498-500. (Pubitemid 32335951)
22. Wang L, Zhang Z, Brock A, Schultz PG (2003) Addition of the keto functional group to the genetic code of Escherichia coli. Proc Natl Acad Sci USA 100:56-61. (Pubitemid 36078029)
23. Young TS, Ahmad I, Yin JA, Schultz PG (2010) An enhanced system for unnatural amino acid mutagenesis in E. coli. J Mol Biol 395:361-374.
24. Liu W, Brock A, Chen S, Chen S, Schultz PG (2007) Genetic incorporation of unnatural amino acids into proteins in mammalian cells. Nat Methods 4:239-244. (Pubitemid 46358874)
25. Hutchins BM, et al. (2011) Site-specific coupling and sterically controlled formation of multimeric antibody fab fragments with unnatural amino acids. J Mol Biol 406:595-603.
26. Hutchins BM, et al. (2011) Selective formation of covalent protein heterodimers with an unnatural amino acid. Chem Biol 18:299-303.
27. Dirksen A, Hackeng TM, Dawson PE (2006) Nucleophilic catalysis of oxime ligation. Angew Chem Int Ed Engl 45:7581-7584. (Pubitemid 44851688)
28. Ross JS, et al. (2009) The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14:320-368.
29. Krop IE, et al. (2010) Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 28:2698-2704.
30. Doronina SO, et al. (2008) Novel peptide linkers for highly potent antibody-auristatin conjugate. Bioconjug Chem 19:1960-1963.
31. Oflazoglu E, et al. (2008) Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res 14:6171-6180.
32. Zhao RY, et al. (2011) Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. J Med Chem 54:3606-3623.
33. Jones DS, et al. (2001) Synthesis of LJP 993, a multivalent conjugate of the N-terminal domain of β2GPI and suppression of an anti-β2GPI immune response. Bioconjug Chem 12:1012-1020. (Pubitemid 33136873)
34. Chambers AF (2009) MDA-MB-435 and M14 cell lines: Identical but not M14 melanoma? Cancer Res 69:5292-5293.
35. Hollestelle A, Schutte M (2009) Comment Re: MDA-MB-435 and M14 cell lines: Identical but not M14 Melanoma? Cancer Res 69:7893-7893.
36. Prat A, et al. (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12:R68.
37. Kazane SA, et al. (2012) Site-specific DNA-antibody conjugates for specific and sensitive immuno-PCR. Proc Natl Acad Sci USA 109:3731-3736.
38. Alley SC, et al. (2009) The pharmacologic basis for antibody-auristatin conjugate activity. J Pharmacol Exp Ther 330:932-938.
39. Boswell CA, et al. (2011) Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem 22:1994-2004.
40. Gross S, Piwnica-Worms D (2005) Spying on cancer: Molecular imaging in vivo with genetically encoded reporters. Cancer Cell 7:5-15. (Pubitemid 40126378)
41. Klerk CPW, et al. (2007) Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals. Biotechniques 43(1, Suppl):7-13, 30.
42. O'Neill K, Lyons SK, Gallagher WM, Curran KM, Byrne AT (2010) Bioluminescent imaging: A critical tool in pre-clinical oncology research. J Pathol 220:317-327.
43. Staflin K, et al. (2010) Targeting activated integrin alphavbeta3 with patient-derived antibodies impacts late-stage multiorgan metastasis. Clin Exp Metastasis 27:217-231.